

Mechanisms of Stimulation for Pain Alleviation

NCT06741579

Status	RECRUITING
Phase	Phase 3
Sponsor	Stanford University
Enrollment	148 participants

Key Eligibility Criteria

Inclusion (8)

- Adults aged 18 or older with clinically diagnosed unilateral CNP in the lower back, pelvis, or lower extremities, defined (per IASP classification) as persistent or recurrent neuropathic pain caused by a peripheral nerve lesion, history of a plausible nerve trauma, pain onset in temporal relation to the trauma, and pain distribution within the innervation territory of a peripheral nerve (or nerves).¹⁴ Negative and positive sensory symptoms or signs must be compatible with the innervation territory of the affected nerve. Can be post-traumatic, post-surgical, nerve compression, nerve ischemia, peripheral nerve injury, painful scar, nerve entrapment, mononeuropathy with or without loss of motor function
 - Patients enrolled in this study must already have been referred for or have an existing order for PNS therapy (either Nalu or SPR SPRINT), prior to consent and enrollment in this study, as part of their routine medical care. Patients cannot receive a referral for PNS device as part of the study procedures.
 - Positive response (at least 50% pain relief) to diagnostic nerve block(s) at the suspected site(s) of CNP.
 - Chronic (at least 6 months duration), intractable peripheral neuropathic pain; any nociceptive pain must be less prominent than the neuropathic pain.
 - Fluent in English writing, reading, and speaking
- ... and 3 more (see full listing online)

Exclusion (23)

- Conditions causing inability to complete assessments (education, cognitive ability, mental status, medical status)
 - Active cancer diagnosis, active malignant neoplasm (metastatic or local) or evidence of paraneoplastic syndrome
 - Painful polyneuropathy (e.g., metabolic, autoimmune, familial, infectious disease, environmental toxins, treatment with neurotoxic drug)
 - Chronic central neuropathic pain (e.g., spinal cord injury, brain injury, multiple sclerosis)
 - Peripheral vascular disease
- ... and 18 more (see full listing online)

Locations (1 total)

Stanford University, Palo Alto, California, United States

<https://clinicaltrials.gov/study/NCT06741579>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).